

Special Issue

Congenital Heart Disease: Technological Innovations in Cardiac Surgery and Interventional Therapy

Message from the Guest Editor

By investing in technological innovations in cardiac surgery and interventional therapy we can improve the quality of life for patient suffering from CHD. The objectives of this Special Issue are to review the current landscape of technological innovations in cardiac surgery and cardiac interventions in pediatric and adult CHD patients. By analyzing the current state we will identify gaps and areas where further innovation is needed. This will help us to focus on developing solutions that address the unmet needs of patients with CHD. We aim to drive forward these innovations and contribute to a better outcome for individuals living with CHD.

Guest Editor

Prof. Dr. Martin Schweiger

1. Pediatric Cardiovascular Surgery, Pediatric Heart Center, Department of Surgery, University Children's Hospital Zurich, 8032 Zurich, Switzerland
2. Children's Research Center, University Children's Hospital Zurich, 8032 Zurich, Switzerland

Deadline for manuscript submissions

20 February 2026



**Journal of
Cardiovascular
Development and
Disease**

**an Open Access Journal
by MDPI**

**Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed**



mdpi.com/si/197831

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).